Lead sponsor
Beijing Chao Yang Hospital
5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
5
Trials led
2
Active
464
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
2
Not applicable
3
Trials by status
Not yet recruiting
2
Completed
2
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 DiabetesBMI ≥24Ph 4Completed230
Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial FunctionBMI ≥25Ph 4Unknown100
The Effect of Semaglutide on the Intestinal Flora in ObesityBMI ≥30not applicableNot yet recruiting40